Newly Diagnosed Multiple Myeloma Clinical Trial Landscape

Active Phase 2 and Phase 3 trials — newly diagnosed multiple myeloma

The table below reflects recruiting and active trials registered on ClinicalTrials.gov targeting newly diagnosed multiple myeloma as of early 2026. DataLookout monitors for new registrations and status changes daily.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting and active trials as of early 2026.

The transformation of NDMM therapy: from VRd to Dara-VRd quadruplets

Multiple myeloma is the second most common hematologic malignancy, with approximately 35,000 new diagnoses per year in the United States. It remains incurable in the vast majority of patients, with current treatment goals centered on achieving deep, durable responses that translate into extended progression-free and overall survival.

The NDMM treatment landscape has undergone a step-change over the past decade. VRd (bortezomib + lenalidomide + dexamethasone) was the previous standard of care, yielding median PFS of approximately 40 months in transplant-eligible patients. The addition of daratumumab — a CD38-targeting IgG1 monoclonal antibody — to VRd in the PERSEUS trial produced a dramatically deeper response: MRD negativity rates increased from 47.5% to 75.2%, and 48-month PFS improved from 67% to 84%.

For transplant-ineligible patients, the MAIA trial (daratumumab + Rd) established Dara-Rd as the standard, while the IMROZ trial demonstrated similar benefit for isatuximab-VRd — giving oncologists two anti-CD38 quadruplet options for TI-NDMM. The net result: anti-CD38 monoclonal antibodies are now embedded in virtually every standard NDMM regimen, and the question for future trial design is no longer "should we add an anti-CD38?" but "what do we add after anti-CD38?"

Transplant eligibility: the organizing principle of NDMM therapy

NDMM trial design and treatment strategy bifurcates around autologous stem cell transplant (ASCT) eligibility. Transplant-eligible (TE) patients — typically those under 70–75 years with good organ function and performance status — receive more intensive induction regimens, mobilization chemotherapy, ASCT, consolidation, and long-term maintenance. Transplant-ineligible (TI) patients receive continuous therapy without ASCT.

Transplant-eligible NDMM: Dara-VRd and the MRD-guided frontier

For TE-NDMM, the current standard is Dara-VRd induction (4–6 cycles), followed by ASCT, then Dara-R maintenance until progression. The AURIGA trial (NCT04898556) tests a refinement: among patients who remain MRD-positive after ASCT, does adding subcutaneous daratumumab to standard maintenance lenalidomide convert them to MRD-negative and improve outcomes? This addresses the 20–25% of TE-NDMM patients who don't achieve MRD negativity even with Dara-VRd + ASCT — a population with significantly inferior prognosis.

A broader question in the field is whether ASCT itself can be omitted for patients who achieve deep MRD negativity after Dara-VRd induction. Multiple trials are evaluating MRD-guided adaptive approaches where transplant is reserved for patients who don't achieve MRD negativity after effective induction. This would represent a major paradigm shift from a procedure-driven to a response-driven ASCT decision.

Transplant-ineligible NDMM: quadruplets and continuous therapy

For TI-NDMM, both Dara-Rd (MAIA) and Isa-VRd (IMROZ) are Phase 3-validated options. IMROZ added bortezomib to the isatuximab backbone, producing MRD negativity rates of 55.5% versus 25.7% for VRd alone and PFS HR of 0.60. The differences between Dara-based and Isa-based regimens are primarily in administration schedules, the exact component combination, and subtle differences in tolerability — not clearly in efficacy, leaving the choice largely based on institutional preference and patient factors.

Bispecific antibodies entering the front-line: consolidation and maintenance trials

The success of BCMA-directed bispecific antibodies (teclistamab, elranatamab) in RRMM has prompted their early-line investigation. The rationale is compelling: bispecifics produce high rates of deep MRD-negative responses even in heavily pretreated RRMM. Moving them earlier — to consolidation after ASCT or as maintenance — might deepen responses achieved with Dara-VRd induction and produce sustained MRD negativity in patients who remain MRD-positive after standard treatment.

The NDMM bispecific strategy does introduce complexity. Bispecifics require step-up dosing to manage cytokine release syndrome (CRS) risk, and their optimal duration of therapy in a consolidation/maintenance setting is unknown. Infection risk from bispecific-induced hypogammaglobulinemia is a significant concern in a setting where patients are already immunocompromised from prior myeloma therapy. Phase 2 data from teclistamab and elranatamab consolidation cohorts are emerging in 2025–2026 and will inform Phase 3 trial design.

CELMoDs: the next-generation IMiD class in front-line development

Cereblon E3 ligase modulators (CELMoDs) — iberdomide and mezigdomide — are the evolutionary successors to lenalidomide and pomalidomide within the immunomodulatory drug class. They bind cereblon with higher affinity and produce deeper degradation of Ikaros and Aiolos transcription factors, generating superior activity in IMiD-resistant cell lines and in patients refractory to lenalidomide and pomalidomide.

The most important question for NDMM: can CELMoDs replace lenalidomide in the Dara-VRd backbone and produce even higher MRD-negativity rates? The SUCCESSOR program (mezigdomide) is testing this hypothesis. If Dara + PI + CELMoD + dex produces deeper responses than Dara-VRd in a Phase 3 setting, CELMoDs could eventually displace lenalidomide in first-line therapy — a massive commercial opportunity given that lenalidomide generates over $6 billion annually in myeloma maintenance alone.

CAR-T in newly diagnosed multiple myeloma: CARTITUDE-5 and early-line ambitions

Ciltacabtagene autoleucel (cilta-cel, Carvykti) is approved for RRMM after at least one prior line of therapy. The CARTITUDE-5 Phase 3 trial (NCT04524936) is testing cilta-cel in transplant-eligible NDMM — comparing it against Dara-VRd + ASCT, the current standard. If CARTITUDE-5 demonstrates superior outcomes versus Dara-VRd + ASCT in TE-NDMM, it would represent one of the most significant shifts in myeloma treatment paradigm in a generation: front-line CAR-T potentially replacing autologous transplant.

The manufacturing challenges of CAR-T remain significant in the NDMM setting. At NDMM, the patient is earlier in their disease course and has not received prior lymphodepleting chemotherapy, potentially changing T-cell fitness and collection efficiency. Manufacturing capacity constraints — which have been the primary limitation on CAR-T access in RRMM — would be even more severe if CAR-T moves to a first-line indication affecting the full NDMM patient population. Scale-up of manufacturing infrastructure is therefore a critical variable in the commercial success of front-line CAR-T.

High-risk cytogenetics: the persistent unmet need

Despite the transformation of NDMM outcomes with daratumumab-based quadruplets, patients with high-risk cytogenetics — particularly deletion 17p (TP53), translocation t(4;14), and translocation t(14;16) — continue to have substantially worse outcomes. These patients often achieve initial MRD-negative responses but relapse faster, suggesting that depth of initial response does not compensate for the aggressive biology driving these tumors.

Multiple dedicated trials for high-risk NDMM are exploring intensification strategies: tandem ASCT (two sequential transplants), adding a fourth or fifth drug to the induction backbone, or using bispecifics early in the consolidation window specifically for high-risk patients. The challenge is that this population is heterogeneous — del(17p) at >50% clone frequency is considered very high risk, while <50% clone frequency confers less-certain risk — and trials have historically been underpowered to make definitive conclusions about the highest-risk subgroups.

Related clinical trials and monitoring resources

Newly diagnosed multiple myeloma is connected to a large adjacent landscape of clinical research. DataLookout monitors related areas including:

• Multiple myeloma clinical trials — full myeloma pipeline across all lines of therapy
• Relapsed/refractory multiple myeloma clinical trials — RRMM is where most trial activity occurs; drugs proven here move earlier to NDMM
• Acute myeloid leukemia clinical trials — hematologic malignancy with overlapping drug classes (venetoclax, HMAs)
• Chronic lymphocytic leukemia clinical trials — CLL shares some investigational agents (bispecifics, BTK inhibitors in related B-cell biology)

Frequently asked questions